Product
Help
Pricing
About
Jobs
Log in
Get started
Author
Add to collection
Michael Bitzer
Institutions:
Universitätsklinikum Tübingen,
University of Tübingen
Observed institutions:
German Cancer Research Center,
Universitätsklinikum Tübingen,
Deutsches Konsortium für Translationale Krebsforschung,
University of Tübingen
ORCID:
0000-0002-4463-8263
Observed ORCID:
0000-0002-4463-8263
OpenAlex ID:
A5037420158
First-line modified FOLFOX plus/minus nivolumab and Ipilimumab or FLOT plus nivolumab in advanced gastroesophageal adenocarcinoma: a phase II multi-cohort IKF-AIO-MOONLIGHT trial
2026
·
Sylvie Lorenzen
, Thorsten Oliver Goetze
, et al.
·
Nature Communications
·
3
PDF
Role prompting modulates linguistic style but not clinical decision structure in GPT-5 tumour board simulation
2026
·
Derna Stifini
, Andrea Della Penna
, et al.
·
npj Digital Medicine
·
2
PDF
App-based assessment of patient-reported outcomes in the Molecular Tumor Board in the Center for Personalized Medicine—(TRACE)
2024
·
Lorenz Dörner
, Lucia Grosse
, et al.
·
Neuro-Oncology Practice
·
2
PDF
Correction to: Complementary role of computed tomography texture analysis for differentiation of pancreatic ductal adenocarcinoma from pancreatic neuroendocrine tumors in the portal‑venous enhancement phase
2021
·
Christian Philipp Reinert
, Karolin Baumgartner
, et al.
·
Abdominal Radiology
·
2
PDF
Combined RAF- and MEK-inhibition in solid cancers with kinase-impaired BRAF mutations (SORATRAM phase I trial).
2025
·
Anna Lena Illert
, Melanie Boerries
, et al.
·
Journal of Clinical Oncology
·
1
Clinical outcome of biomarker-guided therapies in adult neuro-oncology patients: An update from the Tübingen molecular tumor board cohort
2025
·
David Rieger
, Hannes Becker
, et al.
·
Neuro-Oncology Advances
·
1
Assessing the clinical benefit from medical therapies in CNS malignancies: Refining the ESMO Magnitude of Clinical Benefit Scale and the ASCO Value Framework
2025
·
Sylvia C Kurz
, Mirjam Renovanz
, et al.
·
Neuro-Oncology Advances
·
1
PDF
Peribiliäre Zysten
2019
·
Yu-Xiang Ye
, Tobias Hepp
, et al.
·
RöFo - Fortschritte auf dem Gebiet der Röntgenstrahlen und der bildgebenden Verfahren
·
1
Systematic Evaluation of Multilingual Retrieval-Augmented Generation for Gastrointestinal Tumor Board Decision Support
2026
·
Derna Stifini
, Andrea Della Penna
, et al.
·
Research Square
PDF
Organerhaltende Therapie des Rektumkarzinoms
2026
·
Cihan Gani
, Ulrike Schempf
, et al.
·
Die Onkologie
Multi-Omics Tumor Immunogenicity Score Predicts Immunotherapy Outcome and Survival
2025
·
Axel Gschwind
, Nadja Ballin
, et al.
·
Biology
PDF
Qol-23. Towards Patient-reported Outcome Assessment in the Molecular Tumor Board – Cancer Patients Under Targeted Therapy: App-based Assessment of Patient-reported Outcomes (trace)
2022
·
Mirjam Renovanz
, Paula Bombach
, et al.
·
Neuro-Oncology
PDF
Show more works
View as search
Works count:
12
Citation count:
13
H-index:
2
I10-index:
Year
Topic
Type